Sugi Predict

Sugi Predict / Compounds / SCHEMBL3707777

SCHEMBL3707777

SCHEMBL3707777

CCC(Cl)N1CCOCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ HTT P42858 1/20 0.36
▸ DPP4 P27487 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ TSHR P16473 2/20 0.32
▸ MEN1 O00255 3/20 0.31
▸ GAA P10253 1/20 0.31
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ SLC6A2 P23975 1/20 0.31
▸ SLC6A4 P31645 1/20 0.31
▸ SLC6A3 Q01959 1/20 0.31
▸ HRH3 Q9Y5N1 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5219661 0.98 ALDH1A1 (0.38) ALDH1A1KMT2ALMNAMAPTHPGD
SCHEMBL27128838 0.77 — —
SCHEMBL4691097 0.77 — —
Hydrochloric Acid SCHEMBL7460690 0.76 ALDH1A1 (0.34) ALDH1A1KMT2ALMNAMAPTHPGD
SCHEMBL4294178 0.75 SLC6A3 (0.35) ALDH1A1MAPTSLC6A2SLC6A4SLC6A3
SCHEMBL10042012 0.75 ALDH1A1 (0.41) ALDH1A1KMT2ALMNAMAPTHPGD
Hydrochloric Acid SCHEMBL4931478 0.75 SLC6A3 (0.35) SLC6A2SLC6A4SLC6A3
SCHEMBL1994023 0.75 ALDH1A1 (0.41) ALDH1A1KMT2ALMNAMAPTHPGD
SCHEMBL23108665 0.73 KMT2A (0.42) ALDH1A1KMT2ALMNAMAPTHPGD
SCHEMBL5605219 0.73 OPRD1 (0.37) KMT2AMEN1SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1300118-C Preparation method of 4-(3-chlor-4-fluorobenzeneamidocyanogen)-7-methoxy-6-(3-morpholine oxypropyl)quinazoline JIANGSU WUZHONG PHARMACEUTICAL (CN) 2007-02-14 — — CN claimed
CN-1733738-A Preparation method of 4-(3-chlor-4-fluorobenzeneamidocyanogen)-7-methoxy-6-(3-morpholine oxypropyl)quinazoline JIANGSU WUZHONG PHARMACEUTICAL (CN) 2006-02-15 — — CN claimed
CN-112574177-B Pyrimidine derivatives and application thereof in preparing antitumor drugs 陕西师范大学 2023-01-31 — — CN disclosed
CN-112574177-A Pyrimidine derivatives and application thereof in preparing antitumor drugs 陕西师范大学 2021-03-30 — — CN disclosed
WO-2010076810-A2 A PROCESS FOR THE PREPARATION OF GEFITINIB IND-SWIFT LABORATORIES LIMITED (IN) 2010-07-08 — — WO disclosed
EP-1330452-B1 PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES ORTHO MCNEIL PHARM INC (US) 2008-11-26 — — EP disclosed
CN-1300118-C Preparation method of 4-(3-chlor-4-fluorobenzeneamidocyanogen)-7-methoxy-6-(3-morpholine oxypropyl)quinazoline JIANGSU WUZHONG PHARMACEUTICAL (CN) 2007-02-14 — — CN disclosed
CN-1300118-C Preparation method of 4-(3-chlor-4-fluorobenzeneamidocyanogen)-7-methoxy-6-(3-morpholine oxypropyl)quinazoline JIANGSU WUZHONG PHARMACEUTICAL (CN) 2007-02-14 — — CN disclosed
US-20060173034-A1 Novel 4-anilinoquinoline-3-carboxamides ASTRAZENECA AB (SE) 2006-08-03 — — US disclosed
US-7037925-B2 4-anilinoquinoline-3-carboxamides ASTRAZENECA AB (SE) 2006-05-02 — — US disclosed
CN-1733738-A Preparation method of 4-(3-chlor-4-fluorobenzeneamidocyanogen)-7-methoxy-6-(3-morpholine oxypropyl)quinazoline JIANGSU WUZHONG PHARMACEUTICAL (CN) 2006-02-15 — — CN disclosed
US-20030060629-A1 Pyrazine derivatives as modulators of tyrosine kinases ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-03-27 — — US disclosed
WO-2002092571-A1 NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES ASTRAZENECA AB (SE) 2002-11-21 — — WO disclosed
WO-2002024681-A2 PYRAZINE DERIVATIVES AS MODULATORS OF TYROSINE KINASES ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2002-03-28 — — WO disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 — — EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 — — WO disclosed
EP-0495709-A1 Aryltriazine compounds, process for their preparation and pharmaceutical compositions containing them UNIVERSITE LOUIS PASTEUR DE STRASBOURG (FR) 1992-07-22 — — EP disclosed
EP-0076756-B1 PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THERAPEUTICAL COMPOSITIONS CONTAINING THEM ETABLISSEMENTS NATIVELLE S.A. (FR) 1987-03-04 — — EP disclosed
EP-0076756-A1 Pyrazole derivatives, process for their preparation, and therapeutical compositions containing them ETABLISSEMENTS NATIVELLE S.A. (FR) 1983-04-13 — — EP disclosed
US-3994890-A TRANQUILIZERS, ANTIDEPRESSANTS, ANTIINFLAMMATORY CHUGAI SEIYAKU KABUSHIKI KAISHA (JA) 1976-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060173034-A1 Novel 4-anilinoquinoline-3-carboxamides JAK3, JAK2, JAK1 ALDH1A1 3672/4885KMT2A 485/4885LMNA 3813/4885
US-20030060629-A1 Pyrazine derivatives as modulators of tyrosine kinases FLT1, FLT4, KDR ALDH1A1 2950/4885KMT2A 2030/4885LMNA 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.